Toll Free: 1-888-928-9744

Lung Transplantation - Pipeline Review, H1 2015

Published: Jun, 2015 | Pages: 47 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Lung Transplantation - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Lung Transplantation - Pipeline Review, H1 2015', provides an overview of the Lung Transplantation's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Lung Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lung Transplantation and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Lung Transplantation
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Lung Transplantation and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Lung Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Lung Transplantation pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Lung Transplantation
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Lung Transplantation pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Lung Transplantation Overview 6 Therapeutics Development 7 Pipeline Products for Lung Transplantation - Overview 7 Pipeline Products for Lung Transplantation - Comparative Analysis 8 Lung Transplantation - Therapeutics under Development by Companies 9 Lung Transplantation - Pipeline Products Glance 10 Clinical Stage Products 10 Early Stage Products 11 Lung Transplantation - Products under Development by Companies 12 Lung Transplantation - Companies Involved in Therapeutics Development 13 Kamada Ltd. 13 Proteo, Inc. 14 Quark Pharmaceuticals, Inc. 15 Lung Transplantation - Therapeutics Assessment 16 Assessment by Monotherapy Products 16 Assessment by Target 17 Assessment by Mechanism of Action 19 Assessment by Route of Administration 21 Assessment by Molecule Type 23 Drug Profiles 25 alpha-1 proteinase inhibitor (human) - Drug Profile 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Elafin - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 FX-06 - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 R-503 - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 R-801 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Recombinant Human Follistatin - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 RNAi Oligonucleotide for Lung Diseases - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Lung Transplantation - Recent Pipeline Updates 38 Lung Transplantation - Dormant Projects 43 Lung Transplantation - Product Development Milestones 44 Featured News & Press Releases 44 Mar 12, 2015: Elafin combined with cyclosporine promises to overcome limitations of cyclosporine for preventing irreversible damage to transplanted organs 44 Dec 06, 2011: Proteo And Its Subsidiary Announce Major Advances In Elafin Development Program 44 Appendix 46 Methodology 46 Coverage 46 Secondary Research 46 Primary Research 46 Expert Panel Validation 46 Contact Us 46 Disclaimer 47
List of Tables
Number of Products under Development for Lung Transplantation, H1 2015 7 Number of Products under Development for Lung Transplantation - Comparative Analysis, H1 2015 8 Number of Products under Development by Companies, H1 2015 9 Comparative Analysis by Clinical Stage Development, H1 2015 10 Comparative Analysis by Early Stage Development, H1 2015 11 Products under Development by Companies, H1 2015 12 Lung Transplantation - Pipeline by Kamada Ltd., H1 2015 13 Lung Transplantation - Pipeline by Proteo, Inc., H1 2015 14 Lung Transplantation - Pipeline by Quark Pharmaceuticals, Inc., H1 2015 15 Assessment by Monotherapy Products, H1 2015 16 Number of Products by Stage and Target, H1 2015 18 Number of Products by Stage and Mechanism of Action, H1 2015 20 Number of Products by Stage and Route of Administration, H1 2015 22 Number of Products by Stage and Molecule Type, H1 2015 24 Lung Transplantation Therapeutics - Recent Pipeline Updates, H1 2015 38 Lung Transplantation - Dormant Projects, H1 2015 43



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify